Vidarbha News

Propulsion of X-Linked Retinitis Pigmentosa Clinical Trial Pipeline as Novel and Extensive 5+ Therapies Likely to Enter in the Domain | DelveInsight

 Breaking News
  • No posts were found

Propulsion of X-Linked Retinitis Pigmentosa Clinical Trial Pipeline as Novel and Extensive 5+ Therapies Likely to Enter in the Domain | DelveInsight

September 03
13:35 2023

(Albany, United States) As per DelveInsight’s assessment, globally, the X-Linked Retinitis Pigmentosa Pipeline constitutes 5+ key companies continuously working towards developing 5+ X-Linked Retinitis Pigmentosa Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the X-Linked Retinitis Pigmentosa Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, X-Linked Retinitis Pigmentosa NDA approvals (if any), and product development activities comprising the technology, X-Linked Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the X-Linked Retinitis Pigmentosa Pipeline treatment landscape of the report, click here @ X-Linked Retinitis Pigmentosa Pipeline Outlook

 

Key Takeaways from the X-Linked Retinitis Pigmentosa Pipeline Report

  • DelveInsight’s X-Linked Retinitis Pigmentosa Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
  • The leading companies working in the X-Linked Retinitis Pigmentosa market include Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.
  • PromisingX-Linked Retinitis Pigmentosa Pipeline Therapies in the various stages of development include Genetic: AAV5-RPGR, AAV2/5-RPGR, FT-002, Docosahexaenoic Acid OR corn/Soy Oil placebo, and others.
  • On May 2023, Frontera Therapeutics announced a study of Early Phase 1 clinical trials for FT-002. A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
  • On June 2023, MeiraGTx UK II Ltd announced a study of phase 3 clinical trials for Genetic: AAV5-RPGR. A clinical trial of AAV5-RPGR vector for patients with X-linked retinitis pigmentosa (XLRP).
  • On August 2023, Janssen Pharmaceutical K.K. announced a study of Phase 3 clinical trials for AAV5-hRKp.RPGR. The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. Retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).

 

X-Linked Retinitis Pigmentosa Overview

X-linked Retinitis Pigmentosa is a rare, hereditary progressive genetic disorder associated with the gene mutation in chromosome X of an individual. This disorder is characterized by the progressive degeneration of photoreceptor cells in the retina and gradually leading to peripheral vision loss.

 

For further information, refer to the detailed X-Linked Retinitis Pigmentosa Unmet Needs, click here for X-Linked Retinitis Pigmentosa Ongoing Clinical Trial Analysis

 

X-Linked Retinitis Pigmentosa Emerging Drugs Profile

  • BIIB 112 (NSR-RPGR): Biogen
  • 4D-125: 4 D Molecular Therapeutics

 

X-Linked Retinitis Pigmentosa Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for X-linked Retinitis Pigmentosa. The companies which have their X-linked Retinitis Pigmentosa drug candidates in the mid to advanced stage, Phase II/III include, Biogen and others.

 

Request a sample and discover the recent advances in X-Linked Retinitis Pigmentosa Ongoing Clinical Trial Analysis and Medications, Click here for more details @ X-Linked Retinitis Pigmentosa Segmentation

 

X-Linked Retinitis Pigmentosa Drugs and Companies

  • Genetic: AAV5-RPGR: MeiraGTx UK II Ltd
  • FT-002: Frontera Therapeutics
  • Docosahexaenoic Acid OR Corn/Soy Oil Placebo: Retina Foundation of the Southwest/ DSM Nutritional Products Inc.

 

X-Linked Retinitis Pigmentosa Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type 

 

Some of the Companies in the X-Linked Retinitis Pigmentosa Therapeutics Market include-

Biogen, 4D Molecular Therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.

 

Dive deep into rich insights for drugs for the X-Linked Retinitis Pigmentosa Pipeline, Click here @ X-Linked Retinitis Pigmentosa Unmet Needs and Analyst Views

 

Scope of the X-Linked Retinitis Pigmentosa Pipeline Report

  • Coverage- Global
  • Companies- Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, Janssen Research & Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.
  • Therapies- Genetic: AAV5-RPGR, AAV2/5-RPGR, FT-002, Docosahexaenoic Acid OR corn/Soy Oil placebo, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on X-Linked Retinitis Pigmentosa Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. X-linked Retinitis Pigmentosa: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. X-linked Retinitis Pigmentosa – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. X-linked Retinitis Pigmentosa Collaboration Deals
  9. Late Stage Products (Phase II/III)
  10. BIIB 112 (NSR-RPGR): Biogen
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase I/II)
  13. 4D-125: 4 D Molecular Therapeutics
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. X-linked Retinitis Pigmentosa Key Companies
  19. X-linked Retinitis Pigmentosa Key Products
  20. X-linked Retinitis Pigmentosa- Unmet Needs
  21. X-linked Retinitis Pigmentosa- Market Drivers and Barriers
  22. X-linked Retinitis Pigmentosa- Future Perspectives and Conclusion
  23. X-linked Retinitis Pigmentosa Analyst Views
  24. X-linked Retinitis Pigmentosa Key Companies
  25. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market

Categories